According to the American Heart Association, approximately one million open heart surgeries and over 500,000 coronary artery bypass (CPB) surgeries are performed every year. During CPB, blood is routed away from the patient as the surgeon performs Coronary Artery Bypass Grafting (CABG). Complications can occur during this process including significant systemic inflammatory response syndrome (SIRS) which produces a complex and intense "inflammatory" response that can lead to long-lasting cardiac, pulmonary, renal, and neurologic dysfunction in a subset (2-5%) of patients. The US's restriction of a drug, Trasylol®, designed to control CPB bleeding complications in the US made the bleeding and inflammatory-mediated complications as a result of CPB an unmet medical need.
Our in vitro, ex vivo and in vivo studies have shown that our antibody able to reduce systemic inflammatory response generated during CPB. We have shown that our drug is capable of down-regulating an inflammatory response by preventing cellular and complement activation. Our preclinical studies have provided strong evidence that our drug has the following benefits:
NovelMed is currently seeking pharma/venture partners to develop its portfolio of unique therapies for orphan & non-orphan indications.